DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20211487

Use of ebastine a mast cell blocker for treatment of oligozoospermia

Farzana Deeba, Shakeela Ishrat, Jesmine Banu, Shaheen Ara Anawary, Nurjahan Begum

Abstract


Background: Global infertility prevalence rates are difficult to determine, due to the presence of both male and female factors which complicate any estimate which may only address the woman and an outcome of a pregnancy diagnosis or live birth. Although overall male fertility does not appear to have declined, there is evidence for decline in sperm quality. Sperm count below 15×106 sperm/ml is called oligozoospermia. The aim of this study was to evaluate the efficacy of ebastine on sperm count of oligospermic infertile men.

Methods: This was a longitudinal clinical trial study and was conducted in the infertility unit outdoor, Department of Obstetrics and Gynecology, Bangabandhu Sheikh Mujib Medical University, Dhaka. Bangladesh during the period from January 2015 to December 2015. This study was conducted among the male patients and followed purposive sampling technique. Finally, 334 cases were enrolled in this study.

Results: From the total 334 patients in group I, mean sperm count was 10.32±2.71 million/ml in pretreatment and 18.87±9.56 million/ml in post treatment. The difference was statistically significant (p<0.05). In group II, mean sperm count was 10.19±1.75 million/ml in pretreatment and 10.18±1.95 million/ml in post treatment. The difference was not statistically significant (p>0.05). 63.9% oligospermic male showed improvement in sperm count in ebastin group and 18.1% in placebo group.

Conclusions: Sperm count had significantly improved after three months’ treatment period with ebastin than placebo. Therefore, this study suggested that mast cell blocker ebastine can be helpful than placebo to improve the patients’ sperm count with oligospermia.


Keywords


Male fertility, Mast cells, Oligozoospermia, Ebastine, Placebo

Full Text:

PDF

References


Bhasin S, de Kretser DM, Baker HW. Clinical review 64: pathophysiology and natural history of male infertility. J Clin Endocrinal Metab. 194;79(6):1525-9.

Auger J, Kunstmann JM, Czyglik F, Jouannet P. Decline in semen quality among fertile men in Paris during the past 20 years. N Engl J Med. 1995;332(5):281-5.

Hermo L, Lalli M. Monocytes and mast cells in the limiting membrane of human seminiferous tubules. Biol Reprod. 1978;19(1):92-100.

Behrendt H, Hilscher B, Passia D, Hofmann N, Hilscher W. The occurrence of mast cells in the human testis. Acta Anat. 1981;111:14-6.

Maseki Y, Miyake K, Mitsuya H, Kitamura H, Yamada K. Mastocytosis occurring in the testes from patients with idiopathic male infertility. Fertil Steril. 1981;36(6):814-7.

Nistal M, Santamaria L, Paniagua R. Mast cells in the human testis and epididymis from birth to adulthood. Acta Anat. (Basel). 1984;119(3):155-60.

Mekori YA, Metcalfe DD. Mast cells in innate immunity. Immunol Rev. 2000;173:131-40.

Metz M, Maurer M. Mast cells – key effector cells in immune responses. Trends Immunol. 2007;28(5):234-41.

Pejler G, Abrink M, Ringvall M, Wernersson S. Mast cell proteases. Adv Immunol. 2007;167-255.

Pejler G, Ronnberg E, Waern I, Wernersson S. Mast cell proteases: multifaceted regulators of inflammatory disease. Blood. 2010;115(24):4981-90.

Schill WB, Schneider J, Ring J. The use of ketotifen, a mast cell blocker, for treatment of oligo-and asthenozoospermia. Andrologia. 1986;18(6):570-3.

Yamamoto M, Hibi H, Miyake K. Appearance of spermatozoon after administration of mast cell blocker to a patient with azoospermia. Hinyokika Kiyo. 1994;40(6):541-3.

Hibi H, Kato K, Mitsui K. The treatment with tranilast, a mast cell blocker, for idiopathic oligozoospermia. Arch Androl. 2001;47(2):107-11.

Winters BR, Walsh TJ. The Epidemiology of Male Infertility. Urol Clin N Am. 2014;41:195-204.

Chakraborty S, Bonthu N, Swanson BJ, Batra SK. Role of mucins in the skin during benign and malignant conditions. Cancer Lett. 2011;301:127-41.

Roaiah MM, Khatab H, Mostafa T. Mast cells in testicular biopsies of azoospermic men. Andrologia. 2007;39(5):185-9.

Haidl G, Duan YG, Chen SJ, Kohn FM, Schuppe HC, Allam JP. The role of mast cells in ale infertility. Expert Rev Clin Immunol. 2011;7:627-34.

Saharkhiz N, Nikbakht R and Hemadi M. Ketotifen, a mast cell blocker improves sperm motility in asthenospermic infertile men. J Hum Reprod Sci. 2013;6(1):19-22.

Multigner L. Ketotifen improves sperm motility and sperm morphology in male patients with leukocytospermia and unexplained infertility. Fertil Steril. 2006;85:240-3.

Cayan S, Apa DD, Akbay E. Effect of fexofenadine, a mast cell blocker, in infertile men with significantly increased testicular mast cells. Asian J Androl. 2002;4(4):291-4.

Hussein MR, Abou-Deif ES, Bedaiwy MA. Phenotypic characterization of the immune and mast cell infiltrates in the human testis shows normal and abnormal spermatogenesis. Fertil Steril. 2005;83(5):1447-53.

El-Karaksy A, Mostafa T, Shaeer OK, Bahgat DR, Samir N. Seminal mast cells in infertile asthenozoospermic males. Andrologia. 2007;39(6):244-7.

Ellem SJ, Wang H, Poutanen M, Risbridger GP. Increased endogenous estrogen synthesis leads to the sequential induction of prostatic inflammation (prostatitis) and prostatic pre-malignancy. Am J Pathol. 2009;175(3):1187-99.

Hassa H, Yildirim A, Can C, Turgut M. Effect of smoking on semen parameters of men attending an infertility clinic. Clin Exp Obstet Gynecol. 2006;33:19-22.

Mostafa T, Tawadrous G, Roaih MMF, Amer M, Ashour S, Aziz A. Effect of smoking on seminal plasma ascorbic acid in infertile and fertile males. Andrologia. 2006;38:221-4.

Oliva A, Multigner L. Ketotifen improves sperm motility and sperm morphology in male patients with leukocytospermia and unexplained infertility. Fertil Steril. 2006;85(1):240-3.

Moskovtsev SI, Willis J, White J, Mullen JB. Leukocytospermia: Relationship to sperm deoxyribonucleic acid integrity in patients evaluated for male factor infertility. Fertil Steril. 2007;88:737-40.

Matsuki S, Sasagawa I, Suzuki Y. The use of ebastine, a mast cell blocker, for treatment of oligozoospermia. Arch Androl. 2000;44(2):129-32.

Nagai T, Takaba H, Miyake K, Hirabayashi Y, Yamada K. Testicular mast cell heterogeneity in idiopathic male infertility. Fertil Steril. 1992;57(6):1331-6.

Yamamoto M, Hibi H, Miyake K. New treatment of idiopathic severe oligozoospermia with mast cell blocker: results of a single-blind study. Fertil Steril. 1995;64(6):1221-3.